Kornimate/medical-research-clean huggingface dataset:
evaluation of effectiveness of blue code team after in-hospital cardiopulmonary arrest

Conditions: In-hospital Cardiac Arrest

Summary: this study aimed to retrospectively examine patients evaluated by the code blue team on a code blue call in our hospital between 2016-2017. primary outcome: an examination of the survival rates and demographic data of the patients evaluated as an emergency by a code blue call in the period 2016-2017. secondary outcome: to determine the rates of false code blue calls, the clinics giving code blue calls and the relationship between the times of code blue calls and mortality.

this study aimed to retrospectively examine patients evaluated by the code blue team on a code blue call in our hospital between 20016 and 2017. primary outcome: an examination of the survival rates and demographic data of the patients evaluated as an emergency by a code blue call in the period 2016-2017.secondary outcome: to determine the rates of false code blue calls, the clinics giving code blue calls and the relationship between the times of code blue calls and mortality.inclusion criteria: patients throughout the whole hospital for whom a code blue form was completed and who were evaluated by the code blue team on a code blue call.

Eligibility criteria:
inclusion criteria: -patients intervened by code blue team exclusion criteria: * cardiac arrest in the anesthesiology and reanimation intensive care unit * cardiac arrest in the newborn intensive care unit * out-of-hospital cardiac arrest

Keywords: in-hospital cardiac arrest, mortality
prehabilitation for aortic repair patients

Conditions: Aortic Aneurysm

Summary: this is a 2-group study comparing the effect of a "prehabilitation" program to usual care on quality of life and clinical outcomes in patients undergoing elective repair of their thoracic aorta.

patients undergoing elective repair of their thoracic aortic aneurysm will be randomized to a "prehabilitation" program prior to their surgery or to usual care. the prehabilitation program is self-directed program designed to improve health and quality of life prior to surgery. the program is currently offered to general surgery patients; this study will examine the feasibility and acceptability of such a program in a different patient population.

Eligibility criteria:
inclusion criteria: * age 21 years or older * diagnosis of thoracic aortic disease with scheduled repair * medical clearance from cardiothoracic surgeon * ability to provide informed consent * regular use of a smartphone or personal computer exclusion criteria: * conditions that limit walking to a severe degree * current participation in regular physical activity program * acute aortic dissection * recent coronary artery disease events * inability to speak and read english
resiliency training for patients with nf2 via videoconferencing with skype

Conditions: Neurofibromatosis 2

Summary: the aim of this study is to determine, whether the 3rp is feasible, accepted and efficacious and durable when delivered via skype to patients with neurofibromatosis type 2 (nf2) who are deaf or have severe hearing loss using communication access realtime translation (cart) and/or american sign language (asl). this will be a substudy of the irb-approved protocol #2013p002605. it is the same study except it is looking at a particular sub-population: patients with nf2 who are hard of hearing.


Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. can read and speak english at or above the 6th grade level 3. patients with nf2 who are deaf or have severe hearing loss. exclusion criteria: 1. severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality) 2. recent (within past 3 months) change in antidepressant medication 3. use of formal relaxation training (including past participation in a mind-body program), currently or in the past 6 months. 4. unable or unwilling to sign the informed consent documents 5. unable or unwilling to complete psychological assessments online via the redcap system. 6. unable or unwilling to participate in an intervention delivered via videoconferencing with skype. 7. unwilling to use either cart or asl for communication during the skype groups.

Keywords: stress management resiliency skype
bi 655130 long-term treatment in patients with moderate-to severe ulcerative colitis

Conditions: Colitis, Ulcerative

Summary: to evaluate the long-term safety of bi 655130 (spesolimab) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials to evaluate the long-term efficacy of bi 655130 (spesolimab) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials


Eligibility criteria:
inclusion criteria: * male or female patients, aged ≥18 years * signed and dated written informed consent for 1368.17, in accordance with gcp and local legislation prior to admission into the trial * women of childbearing potential (wocbp) must be ready to use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly. a list of contraception methods meeting these criteria is provided in the patient information. note: a woman is considered of childbearing potential (wocbp), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. tuba ligation is not a method of permanent sterilisation. a postmenopausal state is defined as no menses for 12 months without an alternative medical cause. * have completed treatment and the eot visit in the previous trial and are willing and able to continue treatment in 1368.17. exclusion criteria: * have experienced study treatment-limiting adverse events during induction treatment with study drug * have developed any of the exclusion criteria from the original induction study with the following exceptions: * cases of disease limited to the rectum extending \<15 cm past the anal verge are allowed to be included in study 1368.17 * cases of latent tb. patients with newly emerging latent tb during preceding study are allowed to be included in study 1368.17, provided they receive appropriate treatment according to local guidelines
18f fluciclovine (facbc) pet/ct in patients with rising psa after initial prostate cancer treatment

Conditions: Prostate Cancer

Summary: this prospective study will enroll up to 330 men with psa-persistent or psa-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging. consenting participants will be imaged with 18f-fluciclovine pet/ct. site clinicians will manage study subjects per standard practices and will document any change in treatment based on review of 18f-fluciclovine pet/ct findings. all participants will be followed for up to 6 months, with clinical data collected for this study. an interdisciplinary panel will provide expert guidance to local readers on request. the final reporting of the pet/ct scan will be a single report by the local reader following any such discussion.


Eligibility criteria:
inclusion criteria: * history of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy). * suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as : * post prostatectomy: detectable or rising psa level that is \>0.2 ng/ml with a second confirmatory level of \>0.2 ng/ml * post non-prostatectomy: psa rise ≥ 2ng/ml over nadir * negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: whole-body 99mtc bone scintigraphy or naf pet-ct; and either ct or mri of the pelvis (or the abdomen and pelvis). * being considered for salvage therapy * any non-surgical local treatment such as previous cryotherapy, external beam radiation, or hifu (ultrasound) must have occurred at least 1 year in the past. * previous brachytherapy treatment will have occurred at least 2 years in the past * ability to understand and the willingness to sign a written informed consent. exclusion criteria: * ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or lhrh agonist or antagonist) * androgen deprivation therapy (adt) in the past 3 months * history of bilateral orchidectomy * inability to tolerate 18f-fluciclovine pet/ct
recovery and rehabilitation after lung cancer surgery

Conditions: Lung Cancer; Pain; Fatigue; Depression; Breathlessness

Summary: the specific aims of this translational, interdisciplinary, multi-center, international research study with 300 lung cancer patients are to: aim 1 explore how the patients experience the transfer between different locations and between different levels of care at the same location and how they experienced coming home. aim 2 explore lung cancer patients' symptoms, symptom clusters, and changes in symptoms and symptom clusters over time. aim 3 explore interaction between lung cancers patients' symptoms, symptom clusters, health related quality of life and social support.

approximately 2500 patients are diagnosed with lung cancer annually i norway, and approximately 400 of these undergo surgery. many patients report that life after lung cancer surgery is difficult. after surgery, the patients are frequently transferred to a local hospital or to another level of care at the hospital where they were operated. the transfer is critical for patients' safety because communication failure is one of the most common causes of medical error. studies that have analyzed the quality of life of lung cancer patients after surgery reach different conclusions about the patients' quality of life (qol), some studies state that lung cancer patients are back to normal quality of life after 9 months, while others indicate that the patients still have reduced qol two years after surgery. it is difficult to assess the reason for the differences in results as most of the studies used the same qol questionnaire. studies that have evaluated the social support that lung cancer patients receive indicate that lung cancer patients receive less support than other cancer patients. lung cancer patients have a wide range of physical problems (fatigue, dyspnea, coughing and pain) and psychological (depression) problems following surgery. based on findings from this literature review a need exist for improved postoperative follow-up of patients after surgery for lung cancer the proposed study will evaluate the social support, the levels of lung cancer stigma, symptoms and changes in this over time as well as evaluate patient experience with transfer in the immediate postoperative period.

Eligibility criteria:
inclusion criteria: * patients with lung cancer patients above the age of 18 that have been treated with surgery, who are able to speak and understand norwegian, exclusion criteria: * and who suffer no cognitive impairment.

Keywords: symptoms symptoms cluster fatigue depression sleeplessness social support stigma
interstage assessment of remnant liver function in alpps

Conditions: Liver Failure

Summary: post-hepatectomy liver failure is one of the most feared complications by hepatic surgeons. when size of the future liver remnant (flr) is regarded to be not sufficient to sustain post-hepatectomy liver function, techniques as preoperative portal vein embolization or two-stage hepatectomy/associating liver partition and portal vein ligation (alpps) can be performed. alpps induces rapid and extensive hypertrophy by portal vein ligation and in situ liver splitting. to date, feasibility of the second stage of alpps has been assessed only on the basis of standardized future liver remnant or future liver remnant on body weight. however, decrease of liver function between stages, measured by means of laboratory parameters, has been demonstrated to be associated with higher 90-day mortality, regardless of flr volume. in other words, this volumetric increase may not reflect the increase of liver function.

the aim of this study is to determine the predictive value of hepatobiliary scintigraphy with 99mtc-mebrofenin between stages in alpps, in assessing risk of postoperative liver failure and liver failure-related mortality after completion of stage 2.

Eligibility criteria:
inclusion criteria: * hepatobiliary scintigraphy performed between stages in patients submitted to alpps surgery * aged ≥18 exclusion criteria: * known allergy to hida derivatives

Keywords: posthepatectomy liver failure alpps hepatobiliary scintigraphy spect mebrofenin
drug-eluting balloon vs. conventional balloon in the treatment of (re)stenosis (dialysis fistulae)

Conditions: Vascular Access Complication; Restenosis, Vascular Graft; Dialysis Related Complications

Summary: the purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in dialysis fistulae.

drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. stenosis and restenosis is a known problem in dialysis fistulae and drug-eluting devices might be beneficial in this field as well. in the procedure a conventional balloon is passed through the stenosis which is then dilated. after this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon. the stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. follow-up will end at 12 months.

Eligibility criteria:
inclusion criteria: * any dialysis access w/ native vessels warranting intervention exclusion criteria: * previous pta with drug-eluting balloon, thrombolysis, coagulopathy

Keywords: drug-eluting balloon, target lesion revascularization (tlr) restenosis
effect of inhaled td-8236 on allergen-induced asthmatic response

Conditions: Asthma

Summary: this will be a randomized, double-blind, placebo-controlled study. the study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled td-8236 compared to placebo in subjects with mild asthma and a known response to an allergen. each of the three periods will be 14 days, followed by a washout period before the next period.


Eligibility criteria:
inclusion criteria: * male or female, 18 to 65 years of age * willing and able to give informed consent and comply with study requirements * documented physician-diagnosed asthma for ≥ 4 months prior to screening * body mass index (bmi) ≥ 18.0 and ≤ 35.0 kg/m2 at screening and weighs ≥ 50 kg at screening. * women of child bearing potential must have a negative pregnancy test * males and females must use a highly efficient birth control method * pre-bronchodilator fev1 ≥ 70% predicted * documented allergy to at least one common allergen * dual responder to inhaled bronchial challenges * additional inclusion criteria apply exclusion criteria: * positive for hepatitis a, b or c, hiv or tuberculosis * clinically significant abnormalities of laboratory evaluations * have abnormal ecg measurements * any sign of respiratory tract infection within 6 weeks of screening * have a current bacterial, parasitic, fungal or viral infection * history of life-threatening asthma * uses or have used tobacco or nicotine-containing products within 6 months prior to screening * additional exclusion criteria apply

Keywords: td-8236 asthma proof of concept
a single cycle of intravenous immunoglobulin as adjuvant to rituximab in patients with pemphigus: a retrospective cohort study at a tertiary referral center

Conditions: Pemphigus Disease; Rituximab (RTx); Intravenous Immunoglobulin

Summary: pemphigus is a critical autoimmune skin condition mediated by pathogenic autoantibodies mainly against desmoglein (dsg)1 and dsg3, and is traditionally managed with systemic corticosteroids and immunosuppressants.the revolutionary introduction of rituximab (rtx) has opened up a new era of pemphigus treatment by enabling treatment strategies to specifically target cd20+ b cells.studies have highlighted the superior efficacy of rtx combined with systemic corticosteroids, making this therapy first-line treatment for pemphigus patients.currently, the main challenge for pemphigus management is to maximize efficacy while preventing relapses and reducing risks over the course of the disease. rtx achieves maximum effect typically at 4-8 weeks post-treatment, and is associated with an elevated risk of infection.on the other hand, intravenous immunoglobulin (ivig), historically employed for the management of refractory pemphigus, is appreciated for its rapid action and lack of added immunosuppressive risk.it has also been shown to induce long-term clinical remission, and continues to serve as a rescue therapy for difficult cases. while there have been reports on the successful use of rtx and concomitant ivig for treating refractory pemphigus, there is a lack of extensive research weighing the pros and cons of adding ivig to the currently recommended rtx regimen (rheumatoid arthritis protocol, rap). to investigate the efficacy and safety of this combined therapy, we conducted an retrospective cohort study to evaluate the impact of incorporating ivig into the rtx and systemic corticosteroid treatment protocol for pemphigus patients.


Eligibility criteria:
inclusion criteria: 1. patients' files between january 1st, 2019, and december 31st, 2024 from department of dermatology, ruijin hospital, shanghai jiao tong university school of medicine 2. with a diagnosis of pemphigus vulgaris or foliaceus in active stage based on guideline indicators, including typical clinical presentation, positive direct immunofluorescence microscopy findings, and/or detection of serum anti-dsg3 and/or dsg1 immunoglobin (ig)g autoantibodies 3. treated with rtx in association with oral corticosteroids 4. with a follow-up of at least 48 weeks after rtx treatment initiation exclusion criteria: 1. with a diagnosis of other variants of pemphigus (e.g., paraneoplastic pemphigus, herpetiform pemphigus, iga pemphigus); 2. concomitant use of other immunosuppressants (e.g., azathioprine, mycophenolate mofetil, methotrexate) 3. previous administration with ivig for other indications within 12 weeks

Keywords: pemphigus rituximab ivig adverse effect
comparing the effects of ultrasound versus fluoroscopy for sacroiliac joint injections

Conditions: Sacroiliitis

Summary: the purpose of this research project is to compare two different techniques for performing an injection of the sacroiliac joint. although both techniques are safe and accurate, the goal of the study is to determine if one technique is better than the other with respect to improvement in a patient's pain, function, and his or her satisfaction. additionally, the investigators want to determine if one technique is quicker and more efficient than the other.

sacroiliac joint dysfunction is a source of low back pain that causes significant pain and disability. injection of the sacroiliac joint with a local anesthetic/corticosteroid mixture has shown efficacy in treating this condition, when conservative therapy fails. the use of fluoroscopic guidance and anatomic landmarks are traditional methods for performing this injection; however, ultrasound imaging has recently been utilized for performing this procedure. although studies exist that describe and validate the ultrasound technique, no studies exist that compare the techniques with respect to short-term and long-term outcomes. in this study, the primary objective is to determine if a difference exists between a fluoroscopic-guided technique and ultrasound-guided technique with respect to pain and function. a secondary objective is to compare the two techniques with respect to procedural characteristics.

Eligibility criteria:
inclusion criteria: 1. diagnosis of sij dysfunction by history and physical exam * history: either low back pain or buttock pain * exam: either tenderness to palpation over the sij or a positive provocative maneuver (i.e., patrick's, gaenslen's, and/or yeoman's test) 2. failed a trial of conservative therapy which may included medications, physical therapy, or both 3. age \> 18 4. patient agrees to participate in study exclusion criteria: 1. coagulopathy 2. renal or hepatic failure 3. current pregnancy or actively pursuing pregnancy 4. known allergy to local anesthetic or steroids 5. infection at site of needle placement or sij infection 6. patient unable to consent himself or herself 7. patient refusal 8. prior surgical procedures involving the sij 9. body mass index \> 35 kg/m2

Keywords: sacroiliac joint injection fluoroscopy ultrasound
bkm120 as second-line therapy for advanced endometrial cancer

Conditions: Advanced Endometrial Cancer

Summary: this is a prospective multi-center, open-label, single arm, phase ii study to investigate the safety and efficacy of bkm120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line antineoplastic treatment. patients will receive bkm120 orally at a dose of 100 mg/day. availability of tumor specimen (either archival tissue or a fixed fresh biopsy) is mandatory for assessment of the pi3k (phosphatidylinositol 3 kinase (pi3k) pathway activation status.


Eligibility criteria:
inclusion criteria: * ecog (eastern cooperative oncology group) performance status ≤ 2 * histologically confirmed diagnosis of advanced endometrial carcinoma with available tissue specimen for identification of pi3k pathway activation (archival tissue or a fixed fresh biopsy) * one prior line of antineoplastic treatment with a cytotoxic agent * objective progression of disease after prior treatment and at least one measurable lesion as per recist criteria * adequate bone marrow and organ function exclusion criteria: * previous treatment with pi3k and/or mtor inhibitors * symptomatic cns metastases * concurrent malignancy or malignancy within 3 years of study enrollment * active mood disorder as judged by investigator or medically documented history of mood disorder (e.g. major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, etc.), ≥ ctcae grade 3 anxiety * pelvic and/or para-aortic radiotherapy ≤ 28 days prior to enrollment in the study * poorly controlled diabetes mellitus (hba1c \> 8 %) * history of cardiac dysfunction or active cardiac disease as specified in the protocol * impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of bkm120 other protocol-defined inclusion/exclusion criteria may apply

Keywords: advanced endometrial cancer pi3k pathway second-line treatment